Format
Sort by

Send to:

Choose Destination

Results: 3

1.

The association between hydroxyurea treatment and pain intensity, analgesic use, and utilization in ambulatory sickle cell anemia patients.

Smith WR, Ballas SK, McCarthy WF, Bauserman RL, Swerdlow PS, Steinberg MH, Waclawiw MA; Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia.

Pain Med. 2011 May;12(5):697-705. doi: 10.1111/j.1526-4637.2011.01096.x. Epub 2011 Apr 11.

PMID:
21481164
2.

The risks and benefits of long-term use of hydroxyurea in sickle cell anemia: A 17.5 year follow-up.

Steinberg MH, McCarthy WF, Castro O, Ballas SK, Armstrong FD, Smith W, Ataga K, Swerdlow P, Kutlar A, DeCastro L, Waclawiw MA; Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia and MSH Patients' Follow-Up.

Am J Hematol. 2010 Jun;85(6):403-8. doi: 10.1002/ajh.21699.

3.

Climatic and geographic temporal patterns of pain in the Multicenter Study of Hydroxyurea.

Smith WR, Bauserman RL, Ballas SK, McCarthy WF, Steinberg MH, Swerdlow PS, Waclawiw MA, Barton BA; Multicenter Study of Hydroxyurea in Sickle Cell Anemia.

Pain. 2009 Nov;146(1-2):91-8. doi: 10.1016/j.pain.2009.07.008. Epub 2009 Aug 14.

PMID:
19683393
Format
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk